trial

Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia

NCTId NCT00276263
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by Herzog Hospital
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2006-08
Primary completion
—
Eligibility
ALL · 12 Years · 45 Years

Interventions & indications

Drugs
Sarcosine

Sponsors

Herzog HospitalLead Sponsor

Investigators

2
Uriel Heresco-Levy, M.D.Principal Investigator
Bernard A Fischer, M.D.Principal Investigator

Sites

2 total
Jerusalem, IsraelJerusalem, Israel

Facts & assertions

3 sourced
Enrollment
0
Phase
PHASE2
Status
WITHDRAWN
relationships
The graph out of here
drug
Sarcosine
drug
lead_sponsor
Herzog Hospital
company
indication
Psychotic Disorders
indication
Schizophrenic Disorders
indication
Schizophrenias
indication
investigator
Uriel Heresco-Levy, M.D.
person
Bernard A Fischer, M.D.
person